Research Article
Patient Complications after Interscalene Block: A Retrospective Comparison of Liposomal Bupivacaine to Nonliposomal Bupivacaine
Table 2
Varying medication combinations in the liposomal bupivacaine group.
| Drug combination | Volume (mL) range | Volume (mL) median | Number missing |
| LB + 0.25% bupivacaine (N = 130) |
| LB | 5–20 | 10 | 2 | 0.25% bupivacaine | 2–20 | 10 | 1 |
| LB + 0.25% bupivacaine plus epinephrine (N = 229) |
| LB | 5–20 | 10 | 1 | 0.25% bupivacaine plus epinephrine | 2–25 | 10 | 0 |
| LB + 0.5% bupivacaine (N = 118) |
| LB | 5–20 | 10 | 1 | 0.5% bupivacaine | 3–20 | 10 | 0 |
| LB + 0.5% bupivacaine plus epinephrine (N = 225) |
| LB | 7.5–20 | 10 | 0 | 0.5% bupivacaine plus epinephrine | 3–20 | 10 | 0 |
| LB only (N = 79) |
| LB | 10–20 | 15 | 0 |
| LB + 0.5% ropivacaine plus clonidine plus epi (N = 3) |
| LB | 10–15 | 10 | 0 | 0.5% ropivacaine plus clonidine plus epi | 10–15 | 10 | 0 |
|
|
LB: liposomal bupivacaine; N: the number of patients included in that group.
|